-$0.69 EPS Expected for Forty Seven Inc (FTSV) This Quarter

Brokerages expect Forty Seven Inc (NASDAQ:FTSV) to post earnings per share of ($0.69) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Forty Seven’s earnings. The highest EPS estimate is ($0.55) and the lowest is ($0.76). Forty Seven posted earnings per share of ($2.52) during the same quarter last year, which indicates a positive year-over-year growth rate of 72.6%. The company is scheduled to report its next earnings report on Monday, August 12th.

On average, analysts expect that Forty Seven will report full-year earnings of ($2.72) per share for the current financial year, with EPS estimates ranging from ($3.03) to ($2.32). For the next fiscal year, analysts anticipate that the business will report earnings of ($2.62) per share, with EPS estimates ranging from ($3.03) to ($2.23). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Forty Seven.

Forty Seven (NASDAQ:FTSV) last posted its earnings results on Monday, May 13th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14).

Several equities analysts have recently commented on the company. Roth Capital assumed coverage on Forty Seven in a research report on Wednesday, May 29th. They issued a “buy” rating and a $28.00 target price on the stock. Zacks Investment Research raised Forty Seven from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Tuesday, May 14th. HC Wainwright set a $21.00 target price on Forty Seven and gave the company a “buy” rating in a research report on Tuesday, May 14th. Guggenheim assumed coverage on Forty Seven in a research report on Friday, April 12th. They issued a “buy” rating on the stock. Finally, Oppenheimer reaffirmed a “buy” rating on shares of Forty Seven in a research report on Tuesday, March 19th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $26.89.

In related news, insider Mark Anthony Mccamish sold 16,500 shares of the stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $12.10, for a total transaction of $199,650.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Chris H. Takimoto sold 8,000 shares of the stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $16.39, for a total value of $131,120.00. The disclosure for this sale can be found here. Insiders have sold 169,811 shares of company stock worth $2,921,746 in the last three months. 37.40% of the stock is currently owned by company insiders.

Large investors have recently modified their holdings of the stock. BlackRock Inc. lifted its stake in Forty Seven by 34.7% during the first quarter. BlackRock Inc. now owns 1,139,596 shares of the company’s stock worth $18,416,000 after purchasing an additional 293,642 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Forty Seven by 51.2% during the third quarter. JPMorgan Chase & Co. now owns 346,066 shares of the company’s stock worth $5,164,000 after purchasing an additional 117,142 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Forty Seven by 42.8% during the first quarter. Goldman Sachs Group Inc. now owns 178,359 shares of the company’s stock worth $2,882,000 after purchasing an additional 53,498 shares during the last quarter. Vanguard Group Inc lifted its stake in Forty Seven by 144.4% during the third quarter. Vanguard Group Inc now owns 171,060 shares of the company’s stock worth $2,553,000 after purchasing an additional 101,060 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Forty Seven by 144.4% during the third quarter. Vanguard Group Inc. now owns 171,060 shares of the company’s stock worth $2,553,000 after purchasing an additional 101,060 shares during the last quarter. 47.34% of the stock is currently owned by institutional investors and hedge funds.

Forty Seven stock opened at $10.95 on Tuesday. Forty Seven has a 12 month low of $10.50 and a 12 month high of $23.83. The company has a market capitalization of $358.12 million and a PE ratio of -2.92.

About Forty Seven

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody.

Recommended Story: How Do You Make Money With Penny Stocks?

Get a free copy of the Zacks research report on Forty Seven (FTSV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Forty Seven (NASDAQ:FTSV)

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.